Skip to main content
SpringerLink
Log in

Stem Cell Therapy in Osteoarthritis: A Step Too Far?

  • Current Opinion
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Osteoarthritis (OA) is the most common joint disease and, until now, no effective medical treatment has been developed, apart from total joint replacement in end-stage disease. Since mesenchymal stem cells (MSC) can on one hand be the source of newly formed cartilage, and on the other hand inhibit inflammation with their immunomodulatory capacities, these cells are, on a theoretical basis, ideal for the treatment of OA. As a result, MSC-based treatments for OA patients are currently offered worldwide. However, the effectiveness of this treatment and the potential associated risks are not well known. To develop MSC-based treatment of OA into a generally accepted, clinically effective and safe cure, extensive studies have to be performed in controlled experimental and clinical settings. Stem cell therapy is a remedy with the potential for a great future; however, this outlook could be jeopardized if this treatment is introduced too early into clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res 2004;(427 Suppl.):S6–15.

  2. Suri P, Morgenroth DC, Hunter DJ. Epidemiology of osteoarthritis and associated comorbidities. PM R. 2012;4(5 Suppl.):S10–9.

    Article  PubMed  Google Scholar 

  3. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697–707.

    Article  PubMed  Google Scholar 

  4. Haugen IK, Boyesen P, Slatkowsky-Christensen B, Sesseng S, van der Heijde D, Kvien TK. Associations between MRI-defined synovitis, bone marrow lesions and structural features and measures of pain and physical function in hand osteoarthritis. Ann Rheum Dis. 2012;71(6):899–904.

    Article  PubMed  Google Scholar 

  5. Zhang Y, Nevitt M, Niu J, Lewis C, Torner J, Guermazi A, et al. Fluctuation of knee pain and changes in bone marrow lesions, effusions, and synovitis on magnetic resonance imaging. Arthritis Rheum. 2011;63(3):691–9.

    Article  PubMed  Google Scholar 

  6. Hunter W. Of the structure and disease of articulating cartilages, 1743. Clin Orthop Relat Res. 1995;317:3–6.

    PubMed  Google Scholar 

  7. Dell’Accio F, Vincent TL. Joint surface defects: clinical course and cellular response in spontaneous and experimental lesions. Eur Cell Mater. 2010;20:210–7.

    PubMed  Google Scholar 

  8. Bedi A, Feeley BT, Williams RJ III. Management of articular cartilage defects of the knee. J Bone Joint Surg Am. 2010;92(4):994–1009.

    Article  PubMed  Google Scholar 

  9. Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol. 2007;25(10):1177–81.

    Article  PubMed  CAS  Google Scholar 

  10. Qi H, Pei D. The magic of four: induction of pluripotent stem cells from somatic cells by Oct4, Sox2, Myc and Klf4. Cell Res. 2007;17(7):578–80.

    Article  PubMed  CAS  Google Scholar 

  11. Ladenstein R, Peters C, Gadner H. The present role of bone marrow and stem cell transplantation in the therapy of children with acute leukemia. Ann N Y Acad Sci. 1997;824:38–64.

    Article  PubMed  CAS  Google Scholar 

  12. Spencer ND, Gimble JM, Lopez MJ. Mesenchymal stromal cells: past, present, and future. Vet Surg. 2011;40(2):129–39.

    Article  PubMed  Google Scholar 

  13. Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol. 1976;47:327–59.

    Article  PubMed  CAS  Google Scholar 

  14. Roobrouck VD, Clavel C, Jacobs SA, Ulloa-Montoya F, Crippa S, Sohni A, et al. Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells. 2011;29(5):871–82.

    Article  PubMed  CAS  Google Scholar 

  15. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.

    Article  PubMed  CAS  Google Scholar 

  16. Mohal JS, Tailor HD, Khan WS. Sources of adult mesenchymal stem cells and their applicability for musculoskeletal applications. Curr Stem Cell Res Ther. 2012;7(2):103–9.

    Article  PubMed  CAS  Google Scholar 

  17. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient’s bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol. 2007;211(1):27–35.

    Article  PubMed  CAS  Google Scholar 

  18. Tadokoro M, Kanai R, Taketani T, Uchio Y, Yamaguchi S, Ohgushi H. New bone formation by allogeneic mesenchymal stem cell transplantation in a patient with perinatal hypophosphatasia. J Pediatr. 2009;154(6):924–30.

    Article  PubMed  CAS  Google Scholar 

  19. Jones E, Yang X. Mesenchymal stem cells and bone regeneration: current status. Injury. 2011;42(6):562–8.

    Article  PubMed  Google Scholar 

  20. Koga H, Engebretsen L, Brinchmann JE, Muneta T, Sekiya I. Mesenchymal stem cell-based therapy for cartilage repair: a review. Knee Surg Sports Traumatol Arthrosc. 2009;17(11):1289–97.

    Article  PubMed  Google Scholar 

  21. Noth U, Steinert AF, Tuan RS. Technology insight: adult mesenchymal stem cells for osteoarthritis therapy. Nat Clin Pract Rheumatol. 2008;4(7):371–80.

    PubMed  Google Scholar 

  22. Wakitani S, Kimura T, Hirooka A, Ochi T, Yoneda M, Yasui N, et al. Repair of rabbit articular surfaces with allograft chondrocytes embedded in collagen gel. J Bone Joint Surg Br. 1989;71(1):74–80.

    PubMed  CAS  Google Scholar 

  23. Freed LE, Vunjak-Novakovic G, Langer R. Cultivation of cell-polymer cartilage implants in bioreactors. J Cell Biochem. 1993;51(3):257–64.

    Article  PubMed  CAS  Google Scholar 

  24. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. 2003;48(12):3464–74.

    Article  PubMed  Google Scholar 

  25. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis: preliminary report of four patients. Int J Rheum Dis. 2011;14(2):211–5.

    Article  PubMed  Google Scholar 

  26. Varma HS, Dadarya B, Vidyarthi A. The new avenues in the management of osteo-arthritis of knee: stem cells. J Indian Med Assoc. 2010;108(9):583–5.

    PubMed  CAS  Google Scholar 

  27. Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D. Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells. Med Hypotheses. 2008;71(6):900–8.

    Article  PubMed  CAS  Google Scholar 

  28. Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 2008;11(3):343–53.

    PubMed  Google Scholar 

  29. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol. 1996;166(3):585–92.

    Article  PubMed  CAS  Google Scholar 

  30. Wu L, Leijten JC, Georgi N, Post JN, van Blitterswijk CA, Karperien M. Trophic effects of mesenchymal stem cells increase chondrocyte proliferation and matrix formation. Tissue Eng Part A. 2011;17(9–10):1425–36.

    Article  PubMed  CAS  Google Scholar 

  31. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815–22.

    Article  PubMed  CAS  Google Scholar 

  32. El-Badri NS, Maheshwari A, Sanberg PR. Mesenchymal stem cells in autoimmune disease. Stem Cells Dev. 2004;13(5):463–72.

    Article  PubMed  Google Scholar 

  33. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 2007;56(4):1175–86.

    Article  PubMed  CAS  Google Scholar 

  34. Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, Sany J, et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum. 2005;52(5):1595–603.

    Article  PubMed  CAS  Google Scholar 

  35. Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol. 2007;179(3):1595–604.

    PubMed  CAS  Google Scholar 

  36. Black LL, Gaynor J, Adams C, Dhupa S, Sams AE, Taylor R, et al. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther. 2008;9(3):192–200.

    PubMed  Google Scholar 

  37. Black LL, Gaynor J, Gahring D, Adams C, Aron D, Harman S, et al. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet Ther. 2007;8(4):272–84.

    PubMed  Google Scholar 

  38. Glynn SA, Busch MP, Dodd RY, Katz LM, Stramer SL, Klein HG, et al. Emerging infectious agents and the nation’s blood supply: responding to potential threats in the 21st century. Transfusion. 2013;53(2):438–54.

    Article  PubMed  Google Scholar 

  39. Li XY, Ding J, Zheng ZH, Li XY, Wu ZB, Zhu P. Long-term culture in vitro impairs the immunosuppressive activity of mesenchymal stem cells on T cells. Mol Med Report. 2012;6(5):1183–9.

    CAS  Google Scholar 

  40. Stolzing A, Coleman N, Scutt A. Glucose-induced replicative senescence in mesenchymal stem cells. Rejuvenation Res. 2006;9(1):31–5.

    Article  PubMed  CAS  Google Scholar 

  41. Blaha M, Mericka P, Stepanova V, Splino M, Maly J, Jebavy L, et al. Prevention of infection transmission during stem cell transplantation. Folia Microbiol (Praha). 2006;51(6):609–13.

    Article  CAS  Google Scholar 

  42. Ho AD, Wagner W, Franke W. Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy. 2008;10(4):320–30.

    Article  PubMed  CAS  Google Scholar 

  43. Sensebe L, Bourin P, Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther. 2011;22(1):19–26.

    Article  PubMed  CAS  Google Scholar 

  44. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;26(2):8.

    Article  Google Scholar 

  45. Rossignol J, Boyer C, Thinard R, Remy S, Dugast AS, Dubayle D, et al. Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med 2009;13(8B):2547–58.

    Google Scholar 

  46. Mishima Y, Lotz M. Chemotaxis of human articular chondrocytes and mesenchymal stem cells. J Orthop Res. 2008;26(10):1407–12.

    Article  PubMed  Google Scholar 

  47. Baragi VM, Renkiewicz RR, Qiu L, Brammer D, Riley JM, Sigler RE, et al. Transplantation of adenovirally transduced allogeneic chondrocytes into articular cartilage defects in vivo. Osteoarthr Cartil. 1997;5(4):275–82.

    Article  PubMed  CAS  Google Scholar 

  48. Kang R, Marui T, Ghivizzani SC, Nita IM, Georgescu HI, Suh JK, et al. Ex vivo gene transfer to chondrocytes in full-thickness articular cartilage defects: a feasibility study. Osteoarthr Cartil. 1997;5(2):139–43.

    Article  PubMed  CAS  Google Scholar 

  49. Wood JA, Chung DJ, Park SA, Zwingenberger AL, Reilly CM, Ly I, et al. Periocular and intra-articular injection of canine adipose-derived mesenchymal stem cells: an in vivo imaging and migration study. J Ocul Pharmacol Ther. 2012;28(3):307–17.

    Article  PubMed  CAS  Google Scholar 

  50. Perrot P, Heymann D, Charrier C, Couillaud S, Redini F, Duteille F. Extraosseous bone formation obtained by association of mesenchymal stem cells with a periosteal flap in the rat. Ann Plast Surg. 2007;59(2):201–6.

    Article  PubMed  CAS  Google Scholar 

  51. Pelttari K, Winter A, Steck E, Goetzke K, Hennig T, Ochs BG, et al. Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal stem cells correlates with calcification and vascular invasion after ectopic transplantation in SCID mice. Arthritis Rheum. 2006;54(10):3254–66.

    Article  PubMed  CAS  Google Scholar 

  52. Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007;110(4):1362–9.

    Article  PubMed  CAS  Google Scholar 

  53. Hellingman CA, Davidson EN, Koevoet W, Vitters EL, van den Berg WB, van Osch GJ, et al. Smad signaling determines chondrogenic differentiation of bone-marrow-derived mesenchymal stem cells: inhibition of Smad1/5/8P prevents terminal differentiation and calcification. Tissue Eng Part A. 2011;17(7–8):1157–67.

    Article  PubMed  CAS  Google Scholar 

  54. Kafienah W, Jakob M, Demarteau O, Frazer A, Barker MD, Martin I, et al. Three-dimensional tissue engineering of hyaline cartilage: comparison of adult nasal and articular chondrocytes. Tissue Eng. 2002;8(5):817–26.

    Article  PubMed  CAS  Google Scholar 

  55. Wang D, Wang S, Shi C. Update on cancer related issues of mesenchymal stem cell-based therapies. Curr Stem Cell Res Ther. 2012;7(5):370–80.

    Article  PubMed  CAS  Google Scholar 

  56. Tasso R, Augello A, Carida’ M, Postiglione F, Tibiletti MG, Bernasconi B, et al. Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds. Carcinogenesis. 2009;30(1):150–7.

    Article  PubMed  CAS  Google Scholar 

  57. Akay I, Oxmann D, Helfenstein A, Mentlein R, Schunke M, Hassenpflug J, et al. Tumor risk by tissue engineering: cartilaginous differentiation of mesenchymal stem cells reduces tumor growth. Osteoarthr Cartil. 2010;18(3):389–96.

    Article  PubMed  CAS  Google Scholar 

  58. Donnenberg VS, Zimmerlin L, Rubin JP, Donnenberg AD. Regenerative therapy after cancer: what are the risks? Tissue Eng Part B Rev. 2010;16(6):567–75.

  59. Pinilla S, Alt E, Abdul Khalek FJ, Jotzu C, Muehlberg F, Beckmann C, et al. Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett. 2009;284(1):80–5.

    Article  PubMed  CAS  Google Scholar 

  60. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer. 2010;9:129.

    Article  PubMed  Google Scholar 

  61. Jeong JO, Han JW, Kim JM, Cho HJ, Park C, Lee N, et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res. 2011;108(11):1340–7.

    Article  PubMed  CAS  Google Scholar 

  62. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, et al. Spontaneous human adult stem cell transformation. Cancer Res. 2005;65(8):3035–9.

    PubMed  CAS  Google Scholar 

  63. Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010;12(5):576–8.

    Article  PubMed  Google Scholar 

  64. Ben-David U, Mayshar Y, Benvenisty N. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell. 2011;9(2):97–102.

    Article  PubMed  CAS  Google Scholar 

  65. Wong RS. Mesenchymal stem cells: angels or demons? J Biomed Biotechnol 2011;2011:459510. doi:10.1155/2011/459510.

Download references

Acknowledgments

No sources of funding were used to prepare this manuscript. The author has no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Radboud University, Medical Centre, Geert Grooteplein 26, 6525 GA, Nijmegen, The Netherlands

    Peter M. van der Kraan

Authors
  1. Peter M. van der Kraan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter M. van der Kraan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Kraan, P.M. Stem Cell Therapy in Osteoarthritis: A Step Too Far?. BioDrugs 27, 175–180 (2013). https://doi.org/10.1007/s40259-013-0017-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-013-0017-6

Keywords

Search

Navigation